Cell Therapy News Volume 22.41 | Nov 29 2021

    By
    Justin.choi
    -
    0
    32







    201-11-29 | CTN 22.41


    Cell Therapy News by STEMCELL Technologies
    Vol. 22.41 – 29 November, 2021
    TOP STORY

    Targeting p21Cip1 Highly Expressing Cells in Adipose Tissue Alleviates Insulin Resistance in Obesity

    Using single-cell transcriptomics, researchers identified a small, critically important, but previously unexamined cell population, p21Cip1 highly expressing cells, which accumulated in adipose tissue with obesity.
    [Cell Metabolism]

    AbstractPress ReleaseGraphical Abstract
    Request your free copy of the 'Directed Differentiation of Pluripotent Stem Cells' Wallchart
    PUBLICATIONSRanked by the impact factor of the journal

    CRISPR-Enhanced Human Adipocyte Browning as Cell Therapy for Metabolic Disease

    Scientists applied methods to greatly expand human adipocyte progenitors from small samples of human subcutaneous adipose tissue and then disrupted the thermogenic suppressor gene NRIP1 by CRISPR.
    [Nature Communications]

    Full Article

    Neoantigen-Reactive CD8+ T Cells Affect Clinical Outcome of Adoptive Transfer with Tumor-Infiltrating Lymphocytes in Melanoma

    Using barcoded pMHC multimers, investigators provided a comprehensive mapping of CD8+ T cells recognizing neoepitopes in tumor-infiltrating lymphocyte infusion products and blood samples from 26 metastatic melanoma patients who received adoptive cell therapy.
    [Journal of Clinical Investigation]

    Abstract

    Comparing Cord Blood Transplantation and Matched Related Donor Transplantation in Non-Remission Acute Myeloid Leukemia

    The authors investigated the impact of cord blood transplantation, compared to human leukocyte antigen-matched related donor transplantation.
    [Leukemia]

    Full Article

    Runx3 Is Required for Oncogenic Myc Upregulation in p53-Deficient Osteosarcoma

    Scientists detected prominent RUNX3/Runx3 expression in human and mouse p53-deficient osteosarcoma and showed that p53 deficiency promoted osteosarcomagenesis in human and mouse by allowing Runx3 to induce oncogenic Myc expression.
    [Oncogene]

    Abstract

    Sulforaphane Enhances the Antitumor Response of Chimeric Antigen Receptor T Cells by Regulating PD-1/PD-L1 Pathway

    The effect of combined sulforaphane and CAR-T cells was determined in vitro using a co-culture system and in vivo using a xenograft mouse model. Researchers further validated the effects of combination therapy in patients with cancer.
    [BMC Medicine]

    Full Article

    Biliary Atresia-Specific Deciduous Pulp Stem Cells Feature Biliary Deficiency

    Scientists isolated human exfoliated deciduous teeth, namely biliary atresia-SHED, using a standard colony-forming unit fibroblast method and compared characteristics as mesenchymal stem cells to healthy donor-derived control SHED.
    [Stem Cell Research & Therapy]

    Full Article

    Sevoflurane Preconditioning Promotes Mesenchymal Stem Cells to Relieve Myocardial Ischemia/Reperfusion Injury via TRPC6-Induced Angiogenesis

    The authors investigated whether sevoflurane preconditioning could promote mesenchymal stem cells to attenuate myocardial I/R injury via transient receptor potential canonical channel 6 (TRPC6)-induced angiogenesis.
    [Stem Cell Research & Therapy]

    Full Article

    Impact of Donor Types on Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant for Mature Lymphoid Malignancies

    Scientists compared the outcomes of reduced-intensity conditioning transplantation from matched related donors, matched unrelated donors, and umbilical cord blood for mature lymphoid malignancies.
    [Bone Marrow Transplantation]

    Abstract

    Simultaneous Silencing of A2aR and PD-1 as Immune Checkpoints by siRNA-Loaded Nanoparticles Enhances the Immunotherapeutic Potential of Dendritic Cell Vaccine in Tumor Experimental Models

    Investigators inhibited two of the most important immune checkpoints expressed on T cells infiltrated in tumors, including PD-1 and A2aR. Ligation of PD-1 with PD-L1 and A2aR with adenosine significantly suppressed T cell response against tumor cells.
    [Life Sciences]

    Abstract

    Exosomes Derived from miR-129-5p Modified Bone Marrow Mesenchymal Stem Cells Represses Ventricular Remolding of Mice with Myocardial Infarction

    Researchers found that miR-129-5p inhibited high mobility group box 1 (HMGB1) expression in bone marrow mesenchymal stem cells. Myocardial infraction mice treated with exosomes overexpressing miR-129-5p had enhanced cardiac function and decreased expression of HMGB1 and production of inflammatory cytokines.
    [Journal of Tissue Engineering and Regenerative Medicine]

    Abstract
    Connect with us via LiveChat to ask your scientific support questions
    REVIEWS

    Constructing a Cell Microenvironment with Biomaterial Scaffolds for Stem Cell Therapy

    In recent years, emerging biomaterials that provide a supportable cellular microenvironment for transplanted cells have optimized the therapeutic efficacy of stem cells in injured tissues or organs.
    [Stem Cell Research & Therapy]

    Full Article
    INDUSTRY AND POLICY NEWS

    Cytovia and Cellectis Expand Their TALEN® Gene-Edited iNK Partnership to Enable Broader Collaboration in China

    Cytovia Therapeutics, Inc. and Cellectis announced that they have expanded their collaboration of TALEN® gene-edited iPSC-derived natural killer (NK) and chimeric antigen receptor (CAR)-NK cells to include new CAR target and development in China by Cytovia’s joint venture entity, CytoLynx Therapeutics.
    [Cytovia Therapeutics, Inc. (GlobeNewswire, Inc.)]

    Press Release

    CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX110™ for the Treatment of Relapsed or Refractory CD19+ B Cell Malignancies

    CRISPR Therapeutics announced that the FDA granted Regenerative Medicine Advanced Therapy designation to CTX110™, its wholly-owned allogeneic CAR-T cell therapy targeting CD19+ B-cell malignancies.
    [CRISPR Therapeutics]

    Press Release
    FEATURED EVENT

    Immunometabolism at the Crossroads of Obesity and Cancer

    January 16 – 20, 2022
    Banff, Alberta, Canada

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Researcher – Therapeutic Targets

    Flanders Institute for Biotechnology – Leuven, Belgium

    Scientific Researcher – Cancer Immunology

    Genentech – San Francisco, California, United States

    Scientist – Gene Therapy Research

    Sarepta Therapeutics, Inc. – Columbus, Ohio, United States

    Postdoctoral Research Fellow – Tumor Microenvironment

    Fred Hutchinson Cancer Research Center – Seattle, Washington, United States

    Faculty Positions – Cancer Research

    Sidney Kimmel Cancer Center – Philadelphia, Pennsylvania, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Cell Therapy News Twitter